1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Japan-Korea Venture Collab Grows With VC And Regulatory Meetups

 
• By Lisa Takagi

Cross-Asian initiative has already brought several South Korean gene and cell therapy startups and Japanese VCs closer, with further hopes for product development and launches in Japan, regulatory harmonization and gliobalization.

Japan-Korea iPark roundtable
South Korea’s minister of SMEs and Startups Oh Youngju (center) and executives from Korean startups and Japanese pharma firms at a roundtable in Tokyo hosted by Shonan iPark. (Lisa Takagi)

Under a collaborative initiative between Shonan Health Innovation Park (iPark) and South Korea’s government, eight Korean bioventures with gene and cell therapy technologies have recently joined the Japanese biocluster.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m

 
• By Ian Haydock

The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By Lisa Takagi

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

Eisai Expands Dementia Ecosystem Via EcoNaviSta Acquisition

 
• By Lisa Takagi

Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.

Multiple Factors Behind Accelerating Private Equity Plays In Japan, APAC

 
• By Ian Haydock and Lisa Takagi

With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.

More from Cell Therapies

Stock Watch: Are Gene Therapy Prices Too High For Success?

 
• By Andy Smith

The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.

How Miltenyi Hopes To Help Shape India’s CGT Landscape

 
• By Anju Ghangurde

Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.

Orca Swims Toward Commercialization Of T-Cell Therapy

 
• By Alaric DeArment

The biotech announced positive Phase III data for Orca-T, its allogeneic cell therapy, and a company cofounder talked with Scrip about Orca’s commercialization plans.